Ticagrelor is utilized in combination with aspirin to prevent severe life-threatening cardiovascular problems in people with a serious chest pain or heart attack. It also helps to prevent blood clots with coronary stents in patients with a history of acute chest pain or heart attack. The global ticagrelor market is likely to increase at a significant growth rate over the estimated period due to the high number of patient are afflicting from heart problems, increased development of generic drugs and improved market access conditions.
Get PDF Sample Copy (Including Full TOC, List of Tables & Figures, Chart) @
https://www.coherentmarketinsights.com/insight/request-sample/2515
The increasing load of heart disease has a direct effect on global disease and death rate. For example, according to the America Stroke Association and the American Heart Association report 2017 statistics update, cardiovascular disease is listed as the leading cause of death, with 1 in every 3 deaths in the U.S. due to nearly 801,000 deaths in 2017, the same source said. In 2017, approximately 92.1 million American adults were living with some form of cardiovascular disease or post-stroke consequences.
Furthermore, a consequential increase in the number of approvals for vaccine from the US Food and Drug Administration (USFDA) will contribute to the growth of the global ticagrelor market in the estimated period. For example, in July 2018, the USFDA approved ticagrelor tablets manufactured by Alembic Pharmaceuticals to reduce cardiovascular death and stroke in patients with a history of acute coronary syndrome (ACS) or myocardial infarction (MI).
With increasing mergers and acquisitions of key players, North America has a significant share in the global ticagrelor market. For example, in November 2017, PhaseBio Pharmaceuticals, Inc. has entered into a unique, global licensing agreement for PB2452 (formerly MEDI2452) with Phase 1-ready reversal agent MedImmune, AstraZeneca’s Global Biology Research and Development Branch. Ticagrelor binds reversely to receptors present on platelets.
Europe is likely to see significant growth in the global Ticagrelor market, with increasing approval for the development of new Ticagrelor formulations in the region. For example, in May 2017, the European Commission approved marketing authorization for AstraZeneca’s Brilique (ticagrelor) orodispersible tablet (ODT) as a new method of treatment administration. This tablet is effective for patients having difficulty swallowing and in case of emergency.
The size of the global ticagrelor market was valued at US$ 1,145.0 million in 2020, and during the estimated period (2021 – 2028) it is likely to witness a CAGR of 12.3%.
Request PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/2515
Failure of production will hinder the growth of the global ticagrelor market in the estimated period. For example, in October 2016, the Brilinta drug Clopidogrel containing 90 mg ticagrelor, produced by AstraZeneca plc, failed to show its advantage over new indications for peripheral arterial disease (PAD). As a result, Brilinta shares fell 1% in October 2016.
Global Ticagrelor Market: Segmentation
On the basis of Strength, the Global Ticagrelor Market is segmented into:
- 60 mg
- 90 mg
On the basis of Indication, the Global Ticagrelor Market is segmented into:
- Acute Coronary Syndrome
- Ischemic Stroke
On the basis of Distribution Channel, the Global Ticagrelor Market is segmented into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
On the basis of Region, the Global Ticagrelor Market is segmented into:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
Global Ticagrelor Market- Competitive Landscape
Key players performing in the global ticagrelor market are Sun Pharmaceutical Industries Ltd., Avra Laboratories Pvt. Ltd., Anhui Haikang Pharmaceutical Co., Ltd., Natco Pharma Limited, AstraZeneca plc, Eli Lilly and Company, Pfizer Inc., and C.H. Boehringer Sohn AG & Ko. KG.
Reasons to Buy this Ticagrelor Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Ticagrelor market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Ticagrelor market
➡Leading company profiles reveal details of key Ticagrelor market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging Ticagrelor market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
Buy This Complete Business Report With Flat 30% Off @
https://www.coherentmarketinsights.com/insight/buy-now/2515
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Ticagrelor Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Ticagrelor Industry Impact
Chapter 2 Global Ticagrelor Competition by Types, Applications, and Top Regions and Countries
2.1 Global Ticagrelor (Volume and Value) by Type
2.3 Global Ticagrelor (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Ticagrelor Sales, Consumption, Export, Import by Regions
Chapter 5 North America Ticagrelor Market Analysis
Chapter 6 East Asia Ticagrelor Market Analysis
Chapter 7 Europe Ticagrelor Market Analysis
Chapter 8 South Asia Ticagrelor Market Analysis
Chapter 9 Southeast Asia Ticagrelor Market Analysis
Chapter 10 Middle East Ticagrelor Market Analysis
Chapter 11 Africa Ticagrelor Market Analysis
Chapter 12 Oceania Ticagrelor Market Analysis
Chapter 13 South America Ticagrelor Market Analysis
Chapter 14 Company Profiles and Key Figures in Ticagrelor Business
Chapter 15 Global Ticagrelor Market Forecast (2021-2028)
Chapter 16 Conclusions
Research Methodology….
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837